What is the role of novel taxanes in non-small-cell lung cancer?

Clinical Lung Cancer

Volumn 9, Issue SUPPL. 3, 2008, Pages

  Spigel, David R ^a   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Albumin bound paclitaxel; Docetaxel; Paclitaxel polyglumex; STELLAR

Indexed keywords

3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL; 7 METHYLTHIOMETHYLPACLITAXEL; ALBUMIN BOUND DOCETAXEL; ALBUMIN BOUND PACLITAXEL; ANTIHISTAMINIC AGENT; BEVACIZUMAB; BMS 188797; CARBOPLATIN; CISPLATIN; CREMOPHOR; DJ 927; DOCETAXEL; DOCOSAHEXAENOIC ACID PACLITAXEL; GEMCITABINE; IDN 5390; LIPOSOME; MAC 321; MICROSPHERE; NAVELBINE; ORTATAXEL; PACLITAXEL; PACLITAXEL DEPOT; PACLITAXEL POLIGLUMEX; POLYMER; RPR 109881 A; RPR 109881A; STEROID; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MICELLE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PLASMA CLEARANCE; PREMEDICATION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 63849145849     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.s.017     Document Type: Article

References (40)

1. Green MR, Andrews M, Leff R, et al. Adjuvant therapy choices in patients with resected non-small-cell lung cancer: correlation of doctors' treatment plans and relevant phase III trial data. J Oncol Pract 2005; 1:37-42.
2. LamY, Chan C, Kuhn J. Pharmacokinetics and pharmacodynamics of the taxanes. J Clin Pharm Pract 1997; 3:76-93.
3. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-24.
4. Kelly K, Crowley J, Bunn PA, Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-8.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
6. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-91.
7. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005; 23:2937-45.
8. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small- cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol 2003; 21:3909-17.
9. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20:3578-85.
10. Treat J, Belani CP, Edelman MJ, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L). J Clin Oncol 2005; 23(16 suppl):627s (Abstract LBA7025).
11. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998; 16:153-8.
12. Hainsworth JD, Burris HA 3rd, Greco FA. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer. Semin Oncol 2001; 28(3 suppl 9):21-5.
13. Stemmer SM, Cagnoni PJ, Shpall EJ, et al. High-dose paclitaxel, cyclophospha- mide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996; 14:1463-72.
14. Rowinsky EK, Donehower RC. Paclitaxel (Taxol) [published erratum in: N Engl J Med 1995; 333:75]. N Engl J Med 1995; 332:1004-14.
15. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-8.
16. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Tax- otere). Ann Oncol 1993; 4:610-1.
17. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI- 007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8:1038-44.
18. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43.
19. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-803.
20. Green MR, Manikhas GM, Orlov S, et al. Abraxane(R), a novel Cremophor(R)- free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17:1263-8.
21. Rizvi NA, Azzoli C, Miller V, et al. Phase I/II study of ABI-007 as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24(18 suppl):390s (Abstract 7105).
22. Hawkins MJ, Georgy M, Makhson A, et al. Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):397s (Abstract 7132).
23. Hawkins MJ, Manikhas G, Makhson A, et al. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):424s (Abstract 7659).
24. Allerton JP, Hagenstad CT, Webb RT, et al. A phase II evaluation of the com-
25. bination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):395s (Abstract 7127).
26. Reynolds C, Barrera D, Vu DQ, et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first- line patients with advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):411s (Abstract 7610).
27. Bodkin D, Neubauer M, Bolton M. Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small cell lung cancer who are >69 years of age or who have performance status (PS) = 2. Eur J Cancer Suppl 2003; 1:s242.
28. Langer CJ, Socinski MA, O'Byrne KJ. Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): a phase III study. J Clin Oncol 2005; 23(16 suppl):623s (LBA7011).
29. Bonomi P, Langer C, O'Brien M, et al. Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX). J Clin Oncol 2006; 25(18 suppl):374s (Abstract 7040).
30. Oldham FB, Anastassopoulos KP, O'Byrne K, et al. Medical resource utilization (MRU) and costs associated with paclitaxel poliglumex (PPX) compared to gemcitabine (Gem) or vinorelbine (Vin) in non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2007; 25(18 suppl):697s (Abstract 18172).
31. Payne M, Ellis P, Dunlop D, et al. DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J Thorac Oncol 2006; 1:984-90.
32. Camps C, Felip E, Sanchez JM, et al. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 2005; 16:597-601.
33. Szczesna A, Milanowski E, Juhasz E, et al. A phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of platinum-based non-taxane regimen. J Clin Oncol 2006; 24(18 suppl):667s (Abstract 17006).
34. Gurtler JS, Von Pawel J, Spiridonidis CH, et al. An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59-8862) in patients with taxane-resistant non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 23:647 (Abstract 7136).
35. Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007; 18:2009-14.
36. Bonomi P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2007; 7:415-22.
37. Nemunaitis JJ, Leighl N, Miller W, et al. Paclitaxel poliglumex (PPX) in combination with carboplatin (carb) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): preliminary data. J Clin Oncol 2005; 23(16 suppl):677s (Abstract 7230).
38. Ross H, Bonomi P, Langer C, et al. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaive pts with advanced NSCLC and poor performance status (PS2). J Clin Oncol 2006; 24(18 suppl):373s (Abstract 7039).
39. Harries M, O'Donnell A, Scurr M, et al. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Br J Cancer 2004; 91:1651-5.
40. Hidalgo M, Aylesworth C, Hammond LA, et al. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 2001; 19:2493-503.